WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell ...

The live webcasts will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of each event, a replay ...

The live webcasts will also be accessible through the“Events” section of the Investor Relations tab within ProKidney's website at . Following the completion of each event, a replay will be ...

The live webcasts will also be accessible through the "Events” section of the Investor Relations tab within ProKidney's website at www.prokidney.com. Following the completion of each event, a replay ...

WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy ...

14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq ... Demonstrates Consistent Phenotypic Characteristics During Ex Vivo Culture Expansion Process Session Title: Development, Organoids, Injury ...

The live webcast will also be accessibe through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the fireside chat, a ...

As of October 28, 2024, ProKidney Corp had a $225.6 million market capitalization, putting it in the 32nd percentile of companies in the Biotechnology industry. ProKidney Corp does not have a ...